



2018 Clinical Quality Measures for MIPS

Date Modified: January 11, 2018

#	Domain	Measure Title	Measure Description	Type	Denominator	Numerator	Denominator Exclusions/Exceptions
MUSIC1	Patient Safety	Prostate Biopsy Antibiotic Compliance	Compliance with AUA best practices for antibiotic prophylaxis for transrectal ultrasound-guided (TRUS) biopsy	Process	# of prostate biopsies for patients aged 30 or older	# of biopsies where a compliant antibiotic regimen was given	Non-TRUS biopsies; biopsies performed in patients < 30 years of age; biopsies performed in patients that have had prior treatment for prostate cancer
MUSIC3	Efficiency and Cost Reduction	Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a CT scan performed at any time since diagnosis of prostate cancer	Process	# of low-risk prostate cancer patients 30 years or older receiving brachytherapy, EBRT, RP, or cryotherapy	# of low risk prostate cancer patients receiving brachytherapy, EBRT, RP, or cryotherapy who did not have a CT scan since diagnosis of prostate cancer	Prostate cancer patients < 30 years of age; prostate cancer patients receiving an alternate form of treatment from those specified; patients that have had prior treatment for prostate cancer
MUSIC4	Effective Clinical Care	Prostate Cancer: Active Surveillance/Watchful Waiting for Low Risk Prostate Cancer Patients	Proportion of patients with low-risk prostate cancer receiving active surveillance or watchful waiting	Process	# of low-risk prostate cancer patients 30 or older	# of low-risk prostate cancer patients on active surveillance or watchful waiting	Prostate cancer patients < 30 years of age; patients that have had prior treatment for prostate cancer
MUSIC5	Effective Clinical Care	Prostate Cancer: Radical Prostatectomy Cases LOS	Percentage of radical prostatectomy cases with a length of stay > 2 days	Outcome	# of patients aged 30 or older who underwent a radical prostatectomy as treatment for prostate cancer	# of patients with a length of stay > 2 days after radical prostatectomy	Prostate cancer patients < 30 years of age; patients that have had prior treatment for prostate cancer
MUSIC9	Effective Clinical Care	Prostate Biopsy: Repeat Biopsy for Patients with Atypical Small Acinar Proliferation (ASAP)	Proportion of patients undergoing a repeat prostate biopsy within 12 months of their initial biopsy in the registry as a result of a finding of atypical small acinar proliferation (ASAP) as per the NCCN guidelines	Process	# of patients aged 30 or older that had a finding of ASAP on their initial prostate biopsy	# of patients undergoing a repeat prostate biopsy within 12 months of an initial biopsy where there was a finding of ASAP	Patients < 30 years of age; patients that have had prior treatment for prostate cancer
MUSIC10	Effective Clinical Care	Prostate Cancer: Confirmation Testing in low risk AS eligible patients	Percentage of low risk patients that are eligible for active surveillance who receive confirmation testing within 6 months of diagnosis	Process	# of patients aged 30 or older with new diagnosis of low and low-intermediate prostate cancer (Gleason 6 or low volume Gleason 3+4)	# of patients that underwent a second biopsy, MRI, or genomics test within 6 months after date of diagnosis (positive biopsy date)	Prostate cancer patients < 30 years of age; Patients that have had prior treatment for prostate cancer; Patients on watchful waiting
MUSIC11	Effective Clinical Care	Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months since diagnosis	Percentage of patients on active surveillance that have ≥ 2 tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis	Process	# of patients aged 30 or older with new diagnosis of low and low-intermediate prostate cancer (Gleason 6 or low volume Gleason 3+4)	# of patients on active surveillance that have ≥ 2 tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis	Prostate cancer patients < 30 years of age; Patients that have had prior treatment for prostate cancer

AQUA8	Patient Safety	Hospital admissions/complications within 30 days of TRUS Biopsy	Percentage of patients who had TRUS biopsy performed who had ≥ 24 h after the biopsy): infection, hematuria, new antibiotic Rx after biopsy, or inpatient consultation within 30 days	Outcome	# of patients with a TRUS biopsy performed	Number of patients with a TRUS biopsy performed that had infection, hematuria, new antibiotic Rx after biopsy, or inpatient consultation within 30 days	Biopsies performed in patients that have had prior treatment for prostate cancer
102	Efficiency and Cost Reduction	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer	Process	<i>QPP Quality Measure – See Measure Title/Description</i>	<i>QPP Quality Measure – See Measure Title/Description</i>	Patients < 30 years of age; patients that have had prior treatment for prostate cancer
130	Patient Safety	Documentation of Current Medications in the Medical Record	Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration.	Process	<i>QPP Quality Measure – See Measure Title/Description</i>	<i>QPP Quality Measure – See Measure Title/Description</i>	Patients < 30 years of age; patients that have had prior treatment for prostate cancer; patients that are not being screened or treated for prostate cancer
250	Effective Clinical Care	Radical Prostatectomy Pathology Reporting	Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status	Process	<i>QPP Quality Measure – See Measure Title/Description</i>	<i>QPP Quality Measure – See Measure Title/Description</i>	Patients < 30 years of age; patients that have had prior treatment for prostate cancer
265	Communication and Care Coordination	Biopsy Follow-Up	Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician	Process	<i>QPP Quality Measure – See Measure Title/Description</i>	<i>QPP Quality Measure – See Measure Title/Description</i>	Patients < 30 years of age; patients that have had prior treatment for prostate cancer; patients that are not being screened or treated for prostate cancer